Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species^{*}

Received for publication, June 27, 2007, and in revised form, August 6, 2007 Published, JBC Papers in Press, August 13, 2007, DOI 10.1074/jbc.M705274200

Han Ma¹, Wen-Rong Jiang, Nicole Robledo, Vincent Leveque, Samir Ali, Teresa Lara-Jaime, Mohammad Masjedizadeh, David B. Smith, Nick Cammack, Klaus Klumpp, and Julian Symons From the Roche Palo Alto LLC, Palo Alto, California 94304

 β -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent inhibitor of hepatitis C virus (HCV) replication in the subgenomic HCV replicon system, and its corresponding 5'-triphosphate is a potent inhibitor of the HCV RNA polymerase in vitro. In this study the formation of PSI-6130-triphosphate was characterized in primary human hepatocytes. PSI-6130 and its 5'-phosphorylated derivatives were identified, and the intracellular concentrations were determined. In addition, the deaminated derivative of PSI-6130, β -D-2'-deoxy-2'-fluoro-2'-C-methyluridine (RO2433, PSI-6026) and its corresponding phosphorylated metabolites were identified in human hepatocytes after incubation with PSI-6130. The formation of the 5'-triphosphate (TP) of PSI-6130 (PSI-6130-TP) and RO2433 (RO2433-TP) increased with time and reached steady state levels at 48 h. The formation of both PSI-6130-TP and RO2433-TP demonstrated a linear relationship with the extracellular concentrations of PSI-6130 up to 100 µM, suggesting a high capacity of human hepatocytes to generate the two triphosphates. The mean half-lives of PSI-6130-TP and RO2433-TP were 4.7 and 38 h, respectively. RO2433-TP also inhibited RNA synthesis by the native HCV replicase isolated from HCV replicon cells and the recombinant HCV polymerase NS5B with potencies comparable with those of PSI-6130-TP. Incorporation of RO2433-5'monophosphate (MP) into nascent RNA by NS5B led to chain termination similar to that of PSI-6130-MP. These results demonstrate that PSI-6130 is metabolized to two pharmacologically active species in primary human hepatocytes.

Hepatitis C is a major health problem affecting \sim 170 million people worldwide of which around 3 million chronically infected patients reside within the United States (1). The current standard treatment for hepatitis C consisting of pegylated interferon- α and ribavirin only results in about a 50% sustained virological response in patients infected with genotype 1 hepa-

 * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¹ To whom correspondence should be addressed: Roche Palo Alto LLC, 3431 Hillview Ave. Palo Alto. CA 94304 Tel: 650-852-3190: Fax: 650-354-7554. titis C virus (HCV),² the most predominant genotype in the United States and Europe (2-4). New treatment options with improved clinical efficacy and greater tolerability are urgently needed. Novel antiviral agents targeting essential processes of HCV replication as part of optimized combination regimens could achieve increased clinical efficacy and potentially improved adverse event profiles as well as shortened treatment duration as compared with the current standard of care.

HCV RNA replication is mediated by a membrane-associated multiprotein replication complex (5, 6). The HCV NS5B protein, the RNA-dependent RNA polymerase, is the catalytic subunit of the HCV replication complex and is responsible for the synthesis of the RNA progeny and, hence, is a prime target of anti-viral inhibition. Nucleoside analogs have been established as successful antiviral agents targeting the active site of DNA polymerases for the treatment of other viral diseases, including human immunodeficiency virus, hepatitis B virus, and herpes simplex virus (7). The majority of marketed antiviral nucleoside analogs need to be converted to the active 5'-triphosphate forms in the target cells. These nucleotide triphosphate analogs then serve as alternative substrates for the viral DNA polymerases and compete with the incorporation of the corresponding natural nucleotide triphosphates. Upon incorporation by the viral DNA polymerases, the lack of the 3'-hydroxyl group in the deoxyribose moiety leads to the termination of the nascent viral DNA (chain termination).

In the past few years a number of ribonucleoside analogs with 2'-C-methyl, 2'-O-methyl, or 4'-azido substituents on the ribose moiety have been reported to be inhibitors of HCV replication in the subgenomic replicon system (8–13). Prodrugs of two nucleoside analogs, 2'-C-methylcytidine (NM107) and 4'-azidocytidine (R1479), have successfully progressed into clinical development and shown efficacy in HCV-infected patients (14, 15). The corresponding nucleotide triphosphate analogs are substrates for HCV polymerase NS5B and inhibit RNA synthesis activity of HCV NS5B *in vitro*. The incorporation of the nucleotide analogs into nascent HCV RNA strongly reduces the efficiency of further RNA elongation by NS5B,

² The abbreviations used are: HCV, hepatitis C virus; MP, 5'-monophosphate; DP, 5'-diphosphate: TP, 5'-triphosphate: HPI C, high performance liquid

resulting in termination of the nascent RNA product. Therefore, these nucleoside analogs are non-obligatory chain terminators despite the presence of a 3'-hydroxyl group.

Recently, β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) has been identified as a potent and selective inhibitor of HCV replication in the subgenomic replicon system with little or no cytotoxicity in various human cell lines or bone marrow precursor cells (16). The corresponding triphosphate of PSI-6130 is an inhibitor of HCV NS5B competitive with natural CTP (17). Conversion to the active 5'-triphosphate form by cellular kinases is an important part of the mechanism of action for nucleoside analogs. In this study we determined the metabolism of β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in primary human hepatocytes isolated from several donors. We show that β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine was converted to β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine 5'-triphosphate and β-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate via deamination of the phosphorylated cytidylates. Furthermore, we determined the kinetics of the formation of the two active triphosphates and the potency of the two triphosphates against the native HCV replicase and NS5B as well as the molecular mechanism of action of the two triphosphates.

EXPERIMENTAL PROCEDURES

Compounds—β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) was provided by Pharmasset, Inc. (18). A stock solution of 10 mM PSI-6130 was prepared in Dulbecco's phosphatebuffered saline and stored at -20 °C. Tritium-labeled PSI-6130 was synthesized at Roche Palo Alto LLC. The tritiated compound was dissolved in 50% (v/v) ethanol at the concentration of 0.97 mCi/ml with a specific activity of 25.78 Ci/mmol. The stock solution was stored at -20 °C. The phosphorylated derivatives of PSI-6130, namely PSI-6130-MP, -DP, and -TP, were provided by Pharmasset, Inc. β-D-2'-Deoxy-2'-fluoro-2'-Cmethyluridine (RO2433) was synthesized at Roche Palo Alto LLC. RO2433-MP, -DP, and -TP were synthesized by TriLink BioTechnologies (San Diego, CA). Compound stock solutions were prepared in nuclease-free H₂O and stored at -20 °C. 3'-dCTP was purchased from TriLink BioTechnologies.

Cell Culture of Primary Human Hepatocytes—Plated fresh human hepatocytes or hepatocyte suspensions were obtained either from CellzDirect, Inc. or from In Vitro Technologies, Inc. Fresh human hepatocytes obtained from each company were plated or cultured on 6-well collagen coated plates (BD Biosciences #356400) at 1.5 million cells per well using complete serum containing medium obtained from the respective companies. Cells were allowed to recover for at least 18 h before the addition of the compound. All incubations were carried out at 37 °C in a humidified 5% CO₂ atmosphere.

To determine the time course of uptake and phosphorylation of PSI-6130, human primary hepatocytes were incubated with ³H-labeled PSI-6130 at a final concentration of 2 μ M and 10 μ Ci/ml. The compound was added 72, 48, 24, 16, 6 and 1 h before cell harvesting. All time points and untreated cell controls were set up in duplicates.

To determine the dose response of the phosphorylation of

DOCKE

³H-labeled PSI-6130 at 0, 2, 10, 25, 50, 100, and 250 μ M for 24 h. Final concentrations of PSI-6130 were achieved by supplementing ³H-labeled PSI-6130 with non-radiolabeled PSI-6130. Duplicate cell samples were harvested after 24 h of incubation.

To determine the half-life of the triphosphates of PSI-6130 and RO2433, human primary hepatocytes were incubated for 24 h with ³H-labeled PSI-6130 at 2 μ M and 10 μ Ci/ml. The cell monolayer was washed once with the cell culture medium without PSI-6130 and then incubated with fresh medium without PSI-6130 at 0-, 0.5-, 1-, 2-, 4-, 6-, 8-, 24-, 48-, and 72-h time points after the removal of PSI-6130. Duplicate cell samples were set up for each time point. The viable cell numbers of the untreated cell controls for each experiment were determined at the end of the experiment using the trypan blue exclusion method.

Preparation of Cell Extract for High Performance Liquid Chromatography (HPLC) Analysis—At the time of cell harvest the cell culture medium was aspirated, and the cells were washed once with cold phosphate-buffered saline. The cells were scraped into 1 ml of pre-chilled 60% (v/v) methanol and extracted in methanol for 24 h at -20 °C. The extracted samples were then centrifuged at $10,000 \times g$ for 15 min to remove cell debris. The supernatant was transferred to new tubes and evaporated in a speed vacuum at room temperature. The pellets were stored at -80 °C until analysis.

The dried pellets of cell extracts were dissolved in H_2O and filtered though a nanosep MF centrifugal device (Pall Life Sciences #ODM02C34). Before HPLC analysis, cell extract samples were spiked with unlabeled reference standards PSI-6130, RO2433, and their phosphorylated derivatives.

HPLC—The phosphorylated derivatives of PSI-6130 were separated by ion exchange HPLC with a Whatman Partisil 10 SAX (4.6 × 250 mm) column coupled to a radiometric detector (β-RAM, IN/US Systems, Inc.). The mobile phase gradient changed linearly from 0% buffer A (H₂O) to 100% buffer B (0.5 M KH₂PO₄ + 0.8 M KCl) between 4 and 8 min. 100% buffer B ran from 8 to 18 min and changed back to 100% A in 1 min. Buffer A ran until 25 min. The flow rate was 1 ml/min. A ratio of 5:1 Flo Scint IV or Ultima-FloTM AP (PerkinElmer Life Sciences) to column eluent was used for the detection of radiolabeled species in the β-RAM detector (IN/US Systems, Inc.).

The separation of PSI-6130 and RO2433 was performed by reverse phase chromatography with a Zorbax SB-C8 column (4.6 \times 250 mm, 5 μ m) coupled to a radiometric detector (β -RAM). The gradient changed linearly from 100% buffer A (0.01 M heptane sulfonic acid, sodium salt, 0.1% (v/v) acetic acid in water) to 10% buffer B (0.01 M heptane sulfonic acid sodium salt, 0.1% (v/v) acetic acid in 1:1 methanol water) between 0 and 3 min and then changed linearly from 10% buffer B to 95% buffer B between 3 and 18 min. 95% buffer B ran from 18 to 22 min and changed back to 100% A in 0.1 min. Buffer A ran until 25 min. The flow rate was 1 ml/min. PSI-6130 and its intercellular metabolites were identified by comparison of the retention times of the intracellular species in the radiochromatogram with the retention times of nonradioactive reference standards spiked in the cell extract samples and detected by UV

Metabolism and Mechanism of Action of β -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine

Acid Phosphatase Treatment of Cell Extracts—Hepatocyte cell extracts were incubated with acid phosphatase (Sigma #P-0157) at a final concentration of 0.05 mg/ml (23.9 units/ml) at 37 °C for 2.5 h to dephosphorylate any phosphorylated metabolites of PSI-6130. After digestion the samples were analyzed by reversed phase HPLC.

HCV Replicon Assay—The 2209-23 cell line containing a bicistronic HCV subgenomic replicon (genotype 1b, Con1 strain), which expresses a Renilla luciferase reporter gene as an index of HCV RNA replication, has been described before (9). The analysis of inhibition of HCV replication by nucleoside analogs and IC₅₀ determinations were performed as described (12).

HCV Replicase Assay-The membrane-associated native HCV replication complexes were isolated from 2209-23 replicon cell lines as described (6). The inhibition of the RNA synthesis activity of the HCV replicases by PSI-6130-TP was determined as described (6) except that 5 μ l of cytoplasmic replicase complex $(2.5 \times 10^6 \text{ replicon cell equivalent})$ was added to a $20-\mu$ l reaction for 60 min. The inhibition of the RNA synthesis activity of the HCV replicases by RO2433-TP was determined in reactions containing 6.25 μ l of cytoplasmic replicase complex $(3.1 \times 10^6 \text{ replicon cell equivalent})$, 50 mM HEPES, pH 7.5, 10 mM KCl, 10 mM dithiothreitol, 5 mM MgCl₂, 20 μg/ml actinomycin D, 1 mM ATP, GTP, and CTP, 24 µCi of (0.4 µM) $[\alpha$ -³³P]UTP (PerkinElmer #NEG607H), 1 units/µl SUPERase. In (Ambion), 10 mM creatine phosphate, 200 μ g/ml creatine phosphokinase with or without the nucleotide triphosphate inhibitor in a final volume of 20 μ l for 90 min.

HCV Polymerase Assay-The inhibition potency of PSI-6130-TP on the RNA-dependent RNA polymerase activity of recombinant NS5B570-Con1 (genotype 1b, GenBankTM accession number AJ242654) was measured as the incorporation of radiolabeled nucleotide monophosphate into acid-insoluble RNA products as described (6) with the following modifications; IC₅₀ determinations were carried out using 200 nm in vitro transcribed complementary internal ribosome entry site RNA template, 1 μ Ci of tritiated UTP (42 Ci/mmol), 500 μ M ATP, 500 μ M GTP, 1 μ M CTP, 1 \times TMDN buffer (40 mM Tris-HCl, pH 8.0, 4 mM MgCl₂, 4 mM dithiothreitol, 40 mM NaCl) and 200 nm NS5B570-Con1. The inhibition potency of RO2433-TP was determined as described above with the following modification of NTP concentrations: 1 μ Ci of tritiated СТР (39 Ci/mmol), 500 µм АТР, 500 µм GTP, 1 µм UTP. The compound concentration at which the enzyme-catalyzed rate is reduced by 50% (IC₅₀) was calculated using equation,

$$Y = \% \text{ Min} + \frac{(\% \text{ Max} - \% \text{ Min})}{\left(1 + \frac{X}{(\text{IC}_{50})}\right)}$$
(Eq. 1)

where *Y* corresponds to the relative enzyme activity, % Min is the residual relative activity at saturating compound concentration, % Max is the relative maximum enzymatic activity, and *X* corresponds to the compound concentration.

The apparent Michaelis constants $(K_{m(app)})$ for UTP or CTP were measured using assay conditions above with the following

tritiated UTP (0.93 μ M), 4.07 μ M unlabeled UTP, 50 μ M ATP, 50 μ M GTP, and 5 nM to 50 μ M CTP; $K_{m(app)}$ for UTP was measured using 2 μ Ci of tritiated CTP (1.67 μ M), 3.33 μ M unlabeled CTP, 50 μ M ATP, 50 μ M GTP, and 5 nM to 50 μ M UTP. Apparent $K_{m(app)}$ values were calculated by nonlinear fitting using Equation 2,

$$Y = \frac{(V_{\max(app)})X}{K_{m(app)} + X}$$
(Eq. 2)

where *Y* corresponds to the rate of RNA synthesis by NS5B, $V_{\max(app)}$ is the maximum rate or RNA synthesis at saturating substrate concentration, and *X* corresponds to CTP or UTP concentration.

 K_i values were derived from the Cheng-Prusoff Equation (Equation 3) for competitive inhibition,

$$K_{i} = \frac{IC_{50}}{\left(1 + \frac{[NTP]}{K_{m(app)}}\right)}$$
(Eq. 3)

where [NTP] is the concentration of CTP or UTP, and $K_{m(app)}$ is the apparent Michaelis constant for CTP or UTP. Mean K_i values were averaged from independent measurements at 0.2, 1, 5, and 25 μ M CTP or UTP concentrations in triplicate experiments.

Gel-based Nucleotide Incorporation Assay—The RNA template-directed nucleotide incorporation and extension of nucleotide triphosphates and nucleotide triphosphate analogs by HCV polymerase was performed with a 19-nucleotide RNA oligo (5'-AUGUAUAAUUAUUGUAGCC-3') under assay conditions as described (9). The incorporation and extension of CTP and CTP analogs were determined with 5'-end-radiolabeled GG primer and nucleotide triphosphates at the indicated concentrations. The incorporation and extension of UTP and UTP analogs were performed similarly with the same RNA oligo template, 5'-end-radiolabeled GGC primer and nucleotide triphosphates at the indicated concentrations. The radiolabeled RNA products were separated on a TBE-urea acrylamide gel and analyzed using phosphorimaging (GE Healthcare).

RESULTS

Metabolic Profile of PSI-6130-Cellular extracts from primary human hepatocytes incubated with tritium-labeled β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) were resolved by ion exchange HPLC. PSI-6130 and metabolites derived from PSI-6130 were identified by comparing the retention times of radiolabeled species with the retention times of unlabeled reference compounds (Fig. 1A). As shown in Fig. 1B, PSI-6130 (3.0 min) and the 5'-phosphorylated derivatives PSI-6130-DP (13.2 min) and PSI-6130-TP (16.8 min) were identified in human hepatocytes incubated with PSI-6130. In addition, metabolites with retention times corresponding to those of the deaminated product of PSI-6130, β -D-2'-deoxy-2'-fluoro-2'-C-methyluridine (RO2433, 3.8 min) and its corresponding 5'-phosphates RO2433-DP (12.5 min) and RO2433-TP (14.8 min), were detected (Fig. 1B). The monophosphates of the cytidine and uridine analogs PSI-6130-MP




FIGURE 1. Ion exchange HPLC profile of an extract of primary human hepatocytes incubated with PSI-6130. *A*, HPLC separation and retention times of reference compounds PSI-6130 (*a*, 2.5 min), RO2433 (*b*, 3.4 min), RO2433-MP (*c*, 10.2 min), PSI-6130-MP (*d*, 10.4 min), RO2433-DP (*e*, 12.2 min), PSI-6130-DP (*f*, 12.8 min), RO2433-TP (*g*, 14.4 min), and PSI-6130-TP (*h*, 16.3 min). *B*, HPLC profile of an extract from hepatocytes incubated with ³H-labeled PSI-6130 at 2 μ M for 24 h. The retention times in min of the intracellular species are indicated *above* the *radioactive peaks*. Intracellular PSI-6130 and its metabolites were identified by comparing the retention times of the radioactive peaks with those of the UV absorption peaks of reference compounds. There is a calibrated 0.3–0.4-min delay in the retentions times of radioactive trace compared with those of UV trace due to sample traveling from UV detector to radiometric detector.

chromatography conditions and, therefore, co-eluted as a single radioactive peak at 10.6 min. It has been reported that 2'-Omethylcytidine was extensively metabolized to CTP and UTP due to deamination coupled with demethylation of the 2'-substituent or base swapping after glycosidic bond cleavage (19). None of the intracellular metabolites of PSI-6130 was eluted with retention time corresponding to those of 2'-C-methyl-CTP, CTP, and UTP (data not shown). Therefore, there was no evidence for metabolism of PSI-6130 at the 2'-position or evidence for hydrolysis at the glycosidic bond. These data suggest that the primary routes of PSI-6130 metabolism in human hepatocytes were phosphorylation at the 5'-position and deamination at the base.

The hepatocyte extracts were also analyzed by reversed phase HPLC to identify unphosphorylated metabolites of PSI-6130. Two unphosphorylated species with retention times corresponding to PSI-6130 (20.3 min) and its uridine metabolite RO2433 (11.9 min) were observed, with PSI-6130 being the predominant intracellular species (Fig. 2B). There was no evidence of formation of uracil, uridine, cytosine, cytidine, or 2'-deoxycytidine (data not shown). These data agree well with the ion exchange HPLC analysis result and suggest the absence of metabolism at the 2' position and at the glycosidic bond. The phosphorylated metabolites, with the exception of PSI-6130-MP, were not resolved by reversed phase HPLC and co-eluted early as a single broad peak (Fig. 2, A, and B). Acid phosphatase treatment completely converted all the intracellular metabolites to PSI-6130 and RO2433. Therefore, all detected intracellular metabolites represent phosphorylated derivatives of PSI-6130 and RO2433. These results established that PSI-6130 could be phosphorylated to its pharmacologically active 5'-triphosphate analog and that PSI-6130 and/or its phosphates could be deaminated to the corresponding uridine ana-




FIGURE 2. Identification of PSI-6130 and its metabolites by reversed phase HPLC and acid phosphatase treatment. *A*, reversed phase HPLC separation of standard compounds: PSI-6130 (*a*, 20 min), RO2433 (*b*, 11.7 min), PSI-6130-MP (*c*, 7.5 min), (*d*, PSI-6130-DP, PSI-6130-TP, RO2433-MP, RO2433-DP, and RO2433-TP). *B*, reversed phase HPLC profile of an extract from hepatocytes incubated with 25 μ M extracellular PSI-6130 for 24 h. *C*, reversed phase HPLC profile of the same extract after acid phosphatase treatment.

In Vitro Potency of RO2433 and RO2433-TP-As described above, incubation of human hepatocytes with PSI-6130 resulted in the formation of substantial concentrations of the triphosphate of its uridine analog, RO2433-TP. Next we determined whether the PSI-6130-derived uridine analog RO2433 could inhibit HCV replication targeting NS5B polymerase. Huh7 cells containing a subgenomic genotype 1b Con1 strain HCV replicon were incubated with RO2433 or PSI-6130 for 72 h, and dose-dependent inhibition of luciferase reporter activity was determined. RO2433 did not inhibit the HCV replication in the HCV subgenomic replicon system at concentrations up to 100 μ M, whereas PSI-6130 inhibited HCV replication with a mean IC₅₀ of 0.6 μ M under the same assay conditions (Table 1). The lack of potency in the replicon could be related to inefficient compound phosphorylation. To address whether the triphosphate of RO2433 directly inhibits the HCV RNA polymerase, the RNA synthesis activity of the native membrane-associated HCV replication complexes isolated from the same replicon cells was tested in the presence of RO2433-TP. RO2433-TP inhibited the RNA synthesis activity of HCV replicase with a mean IC₅₀ of 1.19 μ M, whereas PSI-6130-TP inhibited HCV replicase with a mean IC₅₀ of 0.34 μ M (Table 1). RO2433-TP also inhibited the RNA synthesis activity of the recombinant HCV Con1 NS5B on a heteropolymeric RNA template derived from the 3'-end of the negative strand of the HCV genome with an IC₅₀ of 0.52 μ M and K_i of 0.141 μ M, as compared with an IC₅₀ of 0.13 μ M and K_i of 0.023 μ M for PSI-6130-TP under the same assay conditions (Table 1). These results established that both RO2433-TP and PSI-6130-TP are intrinsically potent inhibitors of RNA synthesis by HCV

TABLE 1

Potency of PSI-6130 and RO2433 and their 5'-triphosphates

Values presented are the mean ± S.D. from greater than three independent experiments. ND, not determined.

Compound	IC ₅₀			V MCCD CT1L	V NCCD CT11
	Replicon GT1b	NS5B GT1b	Replicase GT1b	K_i NS5B GT1b	K _m NS5B GT1b
		μ_M		μ_M	μ_M
PSI-6130	0.6 ± 0.04	ND	ND	ND	ND
RO2433	>100	ND	ND	ND	ND
PSI-6130-TP	ND	0.13 ± 0.01	0.34 ± 0.1	0.023 ± 0.002	0.22 (CTP)
RO2433-TP	ND	0.52 ± 0.11	1.19 ± 0.09	0.141 ± 0.03	0.37 (UTP)

To investigate the molecular mechanism of HCV polymerase inhibition by PSI-6130-TP and RO2433-TP, we measured their incorporation and chain -termination properties. The incorporation of nucleotide and nucleotide analogs by HCV polymerase NS5B was determined in a gel-based assay using a short RNA template (Fig. 3A). Incorporation of CMP, PSI-6130-MP, and 3'-dCMP was initiated from a ³³P-labeled GG primer (Fig. 3A). Incorporated CMP (Fig. 3B, lane 6) could be further extended in the presence of the next nucleotide UTP (Fig. 3B, lanes 7-10). PSI-6130-TP and 3'-dCTP could also serve as substrates for HCV NS5B and were incorporated into the nascent RNA product (Fig. 3B, lane 11 and 16). After incorporation of PSI-6130-MP or 3'-dCMP, further extension in the presence of the next nucleotide UTP was completed blocked even when UTP was present at concentrations up to 1 mM (Fig. 3B, lane 12-15 and lanes 16-20, respectively). Incorporation of UMP, RO2433-MP, and 3'-dUMP was initiated from a ³³P-labeled GGC primer using the same RNA template (Fig. 3A). Incorporated UMP (Fig. 3C, lane 6) could be further extended in the presence of the next nucleotide ATP (Fig. 3C, lanes 7-10). Fulllength RNA product was observed in the presence of UTP and ATP but absence of CTP (Fig. 3C, lanes 7-10), possibly due to misincorporation by NS5B through G-U wobble base-pairing. HCV NS5B was also able to incorporate RO2433-MP (Fig. 3C, lane 11) and 3'-dUMP (Fig. 3C, lane 16) but was unable to further extend the incorporated RO2433-MP and 3'-dUMP in the presence of the next nucleotide ATP (Fig. 3C, lanes 12-15 and lanes 17-20, respectively). The control samples with GG primer and UTP-only as well as GGC primer and ATP-only did not lead to further extension of the primers, suggesting the incorporation of PSI-6130-MP and RO2433-MP was base-specific. Taken together, these results demonstrate that PSI-6130-TP and RO2433-TP serve as alternative substrates for HCV NS5B and act as functional chain terminators once incorporated into nascent RNA. While this manuscript was under preparation it was reported that the incorporation of PSI-6130-MP into the nascent RNA by HCV polymerase led to chain termination, in agreement with our observations (17).

Kinetics of Phosphorylation of PSI-6130 in Primary Human Hepatocytes—To determine the steady state level of the two triphosphates in hepatocytes after exposure to PSI-6130, primary human hepatocytes from 4 different donors were incubated with 2 μ M PSI-6130 for up to 72 h. The uptake of PSI-6130 by human hepatocytes was fast, and total intracellular activity reached steady state levels at 1 h of PSI-6130 incubation, the earliest time point in this study (Table 2). PSI-6130-TP was detectable in hepatocytes from all 4 donors at 6 h after PSI-6130 template: primer: primer:

3'-CCGAUGUUAUUAAUAUGUA-5' 5'-GG (PSI-6130-TP incorporation) 5'-GGC (RO2433-TP incorporation)




FIGURE 3. **PSI-6130-TP and RO2433-TP are substrates of HCV polymerase and chain-terminators.** *A*, sequence of the RNA template and primers. *B*, the incorporation of CTP and CTP analogs was initiated with GG primer according as described under "Experimental Procedures." The nucleotide triphosphates included in the reactions were as follows: 10 μ M CTP, ATP, and UTP (*lane 1*); 2, 10, 100, and 1000 μ M UTP (*lanes 2–5*); 10 μ M CTP without UTP (*lane 6*) or with 2, 10, 100, and 1000 μ M UTP (*lanes 7–10*); 10 μ M SI-6130-TP without UTP (*lane 1*) 1) or with 2, 10, 100, and 1000 μ M UTP (*lanes 12–15*); 10 μ M 3'-dCTP without UTP (*lane 16*) or with 2, 10, 100, and 1000 μ M UTP (*lane 17–20*). *FL*, full-length. *C*, incorporation of UTP and UTP analogs initiated with GGC primer. The nucleotide triphosphates included in the reactions were as follows: 100 μ M CTP, ATP, and UTP (*lane 1*); 20, 50, and 200 μ M ATP (*lanes 2–5*); 100 μ M UTP without ATP (*lane 6*) or with 2, 20, 50, and 200 μ M ATP (*lanes 7–10*); 100 μ M RO2433-TP without ATP (*lane 11*) or with 20, 50, and 200 μ M ATP (*lanes 12–15*); 100 μ M ATP (*lanes 12–10*); 100 μ M ATP (*lane 13*) or with 20, 50, and 200 μ M ATP (*lanes 12–10*); 100 μ M ATP (*lane 13*) or

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.